Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 257Breast Neoplasms 173Neoplasms 170Colorectal Neoplasms 156Neoplasm Metastasis 127Melanoma 120Recurrence 118Prostatic Neoplasms 118Leukemia, Myeloid, Acute 117Pancreatic Neoplasms 116Ovarian Neoplasms 112Multiple Myeloma 104Lung Neoplasms 96Stomach Neoplasms 92Squamous Cell Carcinoma of Head and Neck 86Triple Negative Breast Neoplasms 85Glioblastoma 82Lymphoma 77Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Carcinoma, Renal Cell 64Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 58Small Cell Lung Carcinoma 55Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

plerixafor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Agammaglobulinemia × 1 year × Clear all
NCT00967785 2026-05-22

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
20 enrolled

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Leukopenia, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡